Just in @TheLancetOncol The PROs from the EV-302 trial, which led to the global approval of 1L EV+pembro in mUC . 👉EV+P led to clinically meaningful pain relief, esp. in pts with moderate-severe baseline pain. 👉EV+P led to better EORTC QLQ-C30 functioning and QoL improvements

RT @RobertoContieri: I’m truly honored to have received the IBCG TravelAward25.My thanks to the panel and to IBCG members. #IBCG25 is the p….

What do you want to know?.

RT @marigfern: Joining @GustavoVillold4 and #FernandoMaluf as LATAM Bladder Cancer experts at the @IBCG_BladderCA in Houston! Adding effort….

RT @neerajaiims: Congratulations Shilpa @shilpaonc and Ben @maughanonc for leading these efforts and congratulations to the team for this w….

RT @LauraBukavinaMD: Recognizing the remarkable efforts of @IBCG_BladderCA board in driving another year of growth and progress for #IBCG25….

Thanks @DrYukselUrun for the shoutout! .Happy to see our review on liquid biopsy in GU cancers just out in @EUplatinum led by @maughanonc .@PGrivasMDPhD @LDyrskjot @dr_coops @EAntonarakis @neerajaiims @montypal .@CleClinicMD @huntsmancancer @UroDocAsh.@UrogerliMD.

The best part about @IBCG_BladderCA besides advancing science & disseminating knowledge is putting the patient in the center of everything. Kicking off day 2 with panel of patient advocates discussing their patient perspectives. @WorldBladderCan @BladderCancerUS .@UroDocAsh

RT @DrYukselUrun: 🩸🧬Liquid biopsy is no longer future!.Minimally invasive, biomarker-driven care!.@EUplatinum @isliquidbiopsy @maughanonc @….

RT @RueschCenter: . @marshalj23 looks at the alarming rise of early-onset GI Cancers. A new review paper in the Journal of the American Med….

RT @marigfern: @shilpaonc @IBCG_BladderCA @UroDocAsh @UrogerliMD @LauraBukavinaMD @jpsade2 @mflazzaro_gu @WesKassouf @achoud72 @mouwlab And….

The brilliant @spsutkaMD proposing development of patient-centric PROs for patients with bladder cancer @IBCG_BladderCA #ibcg25 .Gives a huge shoutout to @crisbergerot for her tremendous work to develop new PRO tool in #kidneycancer with @montypal @tompowles1 . @UroDocAsh

RT @PGrivasMDPhD: Excellent initiative by @IBCG_BladderCA meeting introduced by @UroDocAsh to assess therapy adverse events & PROs specific….

RT @neerajaiims: Who's the best candidate for Lutetium therapy? PSMA PET result matters, but 👉CT/DNA, NGS, and histology also do. Excellen….

RT @AndreaNecchi: Let’s start #IBCG25 @IBCG_BladderCA @UroDocAsh et al!